A Treatment Option for Patients With Primary Advanced or Recurrent Endometrial Cancer – Dec 10th
You are invited to the following presentation: A Treatment Option for Patients With Primary Advanced or Recurrent Endometrial Cancer
Program Details:
• Explore the incidence of endometrial cancer and the importance of MMR/MSI biomarker testing
• Learn about the efficacy and safety data of JEMPERLI in combination with carboplatin and paclitaxel followed by JEMPERLI as a single agent for primary advanced or recurrent endometrial cancer from the RUBY Part 1 trial
• Review the Important Safety Information for JEMPERLI
Presented by: Rebecca Brooks, MD, MD, FACOG
Professor and Chief, Division of Gynecologic Oncology Department of Obstetrics and Gynecology, UC Davis Health
Date and Time: Wednesday, December 10, 2025 at 6:30 PM, PST. RSVP by December 5, 2025
Location: Don Giovanni, 235 Castro St, Mountain View, California 94041. 650-961-9749
Contact: Ronald Palmer ronald.v.palmer@gsk.com or 628-256-5040
Register: To register for this program, visit the following link https://myattendeeresource.com/gsk/251210-gsk-112653
Program Code: 251210-JEM-112653